Back

Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease

3 September 2019 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Darren Keith McGuire

University of Texas Southwestern Medical Center, Dallas (United States of America)

6 More presentations in this session

Presentation thumbnail
Doctor S. Park (Illkirch, FR)
Abstract Slides
Presentation thumbnail
Doctor H. Kondo (Yufu City, JP)
Abstract
Presentation thumbnail
Doctor C. Parco (Ibbenbueren, DE)
Abstract
Presentation thumbnail
Mr J. Ghouse (Copenhagen, DK)
Abstract
Presentation thumbnail
Professor C. Desouza (Omaha, US)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 7 - Pharmacotherapy of diabetes: from bench to bedside

The Event

Event poster

ESC Congress 2019

3 September 2019 14:00 CET
You may be interested in
thumbnail
Congress Session
Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources